Medicine:Noora (vaccine)
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
Noora (Persian: نورا) is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. (lit. White Cypress Plasma Treatment) in Iran.[1][2]
Medical uses
It requires three doses given by intramuscular injection on days 0, 21 and 35.[3]
Pharmacology
Noora is a recombinant RBD protein subunit vaccine.[3]
Manufacturing
Up to 8 December 2021, 5 millions doses have been produced.[4]
Clinical trials
| Phase | Registration number | Start | Number of participants | Age of participants | Ref | ||
|---|---|---|---|---|---|---|---|
| Total | Vaccine | Placebo | |||||
| I | IRCT20210620051639N1 | 25 June 2021 | 70 | 30 (80 µg)
30 (120 µg) |
10 (placebo) | 18–50 years | [3] |
| II | IRCT20210620051639N2 | 10 October 2021 | 300 | 240 | 60 | 18–40 years | [5] |
| III | IRCT20210620051639N3 | 23 December 2021 | 10000 | >18 years | [6] | ||
See also
- Pharmaceuticals in Iran
- COVID-19 pandemic in Iran
- COVID-19 vaccine clinical research
References
- ↑ "IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. https://www.tehrantimes.com/news/462470/IRGC-starts-clinical-trial-of-Noora-coronavirus-vaccine.
- ↑ "IRGC Commander: Iran-Made 'Noora' Coronavirus Vaccine Ready for 2nd Stage of Human Trial". Fars News Agency. 22 August 2021. https://www.farsnews.ir/en/news/14000531000599/IRGC-Cmmander-Iran-Made-%E2%80%98Nra%E2%80%99-Crnavirs-Vaccine-Ready-fr-2nd-Sage-f.
- ↑ 3.0 3.1 3.2 "A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.
- ↑ "5 میلیون دوز واکسن "نورا" تولید شد- اخبار پزشکی - اخبار اجتماعی تسنیم | Tasnim" (in fa). https://www.tasnimnews.com/fa/news/1400/09/17/2622286/5-%D9%85%DB%8C%D9%84%DB%8C%D9%88%D9%86-%D8%AF%D9%88%D8%B2-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D9%86%D9%88%D8%B1%D8%A7-%D8%AA%D9%88%D9%84%DB%8C%D8%AF-%D8%B4%D8%AF.
- ↑ "IRCT | A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population.". https://en.irct.ir/trial/59156.
- ↑ "IRCT |Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAN". https://en.irct.ir/trial/60796.
 |
